Sciwind Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic diseases. Its lead asset, ecnoglutide (XW003), is currently in the NDA stage in China. Leveraging proprietary platforms for oral peptide and long-acting protein therapeutics, Sciwind has built a diverse pipeline targeting GLP-1 and synergistic mechanisms, offering both injectable and oral treatment options for metabolic pateints worldwide.
| Website | http://www.sciwindbio.com |
| Employees | 9 (7 on RocketReach) |
| Founded | 2017 |
| Industry | Biotechnology Research |
| Keywords | Bioscience, Biopharmaceutical, Combination Therapy, Clinical Stage, Therapeutic Candidates, Drug Development, Biotechnology, Pharmaceutical Research, Clinical Trials, Medicine, Healthcare, Life Sciences, Biologics, Therapeutics, Pharmaceutical, Drug Discovery, Health |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, GSK, Genentech, Amgen, Biogen, Lilly India +52 more (view full list) |
Looking for a particular Sciwind Biosciences employee's phone or email?
Sciwind Biosciences Questions
Hai Pan is the CEO of Sciwind Biosciences.
7 people are employed at Sciwind Biosciences.
Top Sciwind Biosciences Employees
-
23
-
恺军 鲍
VP and Head of Commercial Strategy. at Sciwind Biosciences
Shanghai, China -
Haixia Zou
Executive Director at Sciwind Biosciences
Shanghai, China1 -
Yi Qiao
Director of Global Strategy at Sciwind Biosciences
Shanghai, China11 -
Li Jiamin
BD经理 at Sciwind Biosciences
Beijing, CN
Related Companies
G2Crowd Trusted
300K+
Plugin Users
